Avelumab Injection + Methotrexate 1 GM Injection
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gestational Trophoblastic Neoplasias (GTN)
Conditions
Gestational Trophoblastic Neoplasias (GTN)
Trial Timeline
Feb 12, 2020 → Oct 12, 2028
NCT ID
NCT04396223About Avelumab Injection + Methotrexate 1 GM Injection
Avelumab Injection + Methotrexate 1 GM Injection is a phase 1/2 stage product being developed by Merck for Gestational Trophoblastic Neoplasias (GTN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04396223. Target conditions include Gestational Trophoblastic Neoplasias (GTN).
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04396223 | Phase 1/2 | Recruiting |
Competing Products
18 competing products in Gestational Trophoblastic Neoplasias (GTN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin | Eli Lilly | Phase 3 | 77 |
| Insulin LISPRO + Insulin, Long-Acting and Insulin | Eli Lilly | Approved | 85 |
| Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| Metformin + placebo | Novo Nordisk | Approved | 84 |
| Metformin XR plus placebo + Metformin XR plus liraglutide | Novo Nordisk | Phase 3 | 76 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Liraglutide + Placebo | Novo Nordisk | Approved | 84 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| growth hormone | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Omnitrope | Sandoz Group | Approved | 82 |
| Inhaled Technosphere Insulin | MannKind Corp | Phase 2/3 | 60 |